Pune, India -- (SBWIRE) -- 12/19/2017 -- Astellas Pharma (Japan), Sanofi (France), Regeneron Pharmaceuticals, Inc. (US), Valeant Pharmaceuticals (Canada), Anacor Pharmaceuticals (US), Novartis (Switzerland) are some of the prominent players at the forefront of competition in the Global Atopic Dermatitis Market and are profiled in MRFR Analysis.

Global Atopic Dermatitis – Market Overview

Atopic dermatitis also known as AD, is a condition that makes your skin red and itchy. It's basically in children yet can occur at any age. Atopic dermatitis is enduring (chronic) and tends to flare periodically and after that subside. It might be accompanied by asthma or fever.

Get a Sample Report @ https://www.marketresearchfuture.com/sample_request/1610 .

The global market for AD treatment market will be majorly driven by, acquisition, merger new product launch, the number of patients suffering from AD has significantly increased during the last three decades.

Novartis bolsters innovative dermatology portfolio through acquisition of Ziarco Group Limited. Acquisition to add a once-daily oral H4 receptor antagonist, ZPL389, to treat atopic dermatitis, commonly known as eczema, to the Novartis industry-leading pipeline. Investigational ZPL389 showed a clinically & statistically significant improvement of eczema lesions, leading to a significant reduction in EASI score compared to placebo after eight weeks of treatment with a favourable safety profile. Novartis announced that it has entered into a definitive agreement for the acquisition of Ziarco Group Limited, a privately held company focused on the development of novel treatments in dermatology. This acquisition would add a once-daily oral H4 receptor antagonist in development for atopic dermatitis (AD), commonly known as eczema, to complement the growing Novartis dermatology portfolio and pipeline. The transaction is subject to customary closing conditions, including regulatory approval. Ziarco's lead investigational product, ZPL389, is a potential first-in-class oral treatment for moderate-to-severe eczema. Eczema is a chronic, itchy, inflammatory skin condition found in millions of children and adults worldwide. In addition, it is associated with sleep loss and a significant reduction in quality of life. Currently, no safe, effective, and well-tolerated oral treatments are available for the moderate-to-severe form of this condition. Novartis strengthen dermatology capabilities shown by the recent successful launches of Cosentyx & Xolair. Now company excited about a potential new medicine for people with eczema through the acquisition of Ziarco and the addition of a first-in-class oral H4 receptor antagonist to our growing pipeline.

Order Single User License Copy of 115 Premium Pages is Available @ https://www.marketresearchfuture.com/reports/atopic-dermatitis-market-1610 .

Global Atopic Dermatitis Market – Competitive Analysis

As the market seems to be attractive, growing and profitable, at the same time market has witnessed intense rivalry among existing competitors. Many new entrants expected to enter into Global Atopic Dermatitis market. There are many big players in the Global Atopic Dermatitis market such as: Astellas Pharma (Japan), Sanofi (France), Regeneron Pharmaceuticals, Inc. (US), Valeant Pharmaceuticals (Canada), Anacor Pharmaceuticals (US), Novartis (Switzerland)

The report for Global Atopic Dermatitis Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

Global Atopic Dermatitis Market – Regional Analysis

Globally North America is the largest market for Atopic Dermatitis. The North American market for Atopic Dermatitis is expected to grow at a healthy CAGR in upcoming years. This is due to low availability of drugs for the treatment of atopic dermatitis in markets. Europe is the second-largest market for Atopic Dermatitis. Whereas Asia pacific is expected to be a growing market for Atopic Dermatitis market and expected to grow at a rapid rate.

Ask to Expert @ https://www.marketresearchfuture.com/enquiry/1610 .

About Market Research Future
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.